Tag Archives: Drug development
MTC Roundtable Series: Up in Smoke – A Discussion on Maryland’s Medical Cannabis Industry
Join panelists Sterling Crockett of AGRiMED Industries and Stacey Udell of HBK Valuation Group for a discussion on Maryland’s burgeoning medical cannabis industry. Panelists will examine all stages of the medical cannabis industry, including: research and development, legalization, legislature, establishing a business, taxation and trends in the industry. Sponsored by Glass Jacobson Financial Group
Innovation Speaker Series: Opioid Epidemic - State of Emergency
Innovations to Fight the Opioid Crisis Opioid misuse and addiction is an ongoing and rapidly evolving public health crisis. Millions of Americans suffer from opioid use disorder, and millions more suffer from chronic pain. The urgency and scale of this crisis calls for innovative scientific solutions. As part of a government-wide effort to address this…
2017 Academic Drug Discovery Colloquium
The focus of the second collaboration between ASPET and the Academic Drug Discovery Consortium (ADDC) will explore a critical domain to innovation – how to obtain funding.
NIH Injects New Moxie Into Drug Development
Like making a new pair of shoes out of supple old leather, The National Center for Advancing Translational Sciences (NCATS) spearheads the newly minted endeavor by the National Institutes of Health (NIH) to speed the process of delivering new and re-purposed therapeutics to the bedside. This $575 million dollar Translational Research Center will be lead by newly appointed Director,…
Is Working With The Government Really Like Working With A Slow-Moving Bulldog?
Working with the FDA is apparently so difficult that one federal device regulation expert compared the FDA to “a slow-moving bulldog,” reported Gus Sentementes of the Baltimore Sun. (His article Maryland’s Biotech Pitch: We know the Feds is well worth reading.) It’s fascinating that the requirements of the FDA are so intricate that being able to waltz with…